Business Context and Reporting Period
Company: Apimeds Pharmaceuticals US, Inc. (APUS)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A clinical-stage biopharmaceutical company developing Apitox, a bee venom-based therapeutic for osteoarthritis and multiple sclerosis. The company has no commercial revenue and is focused on FDA approval processes.
Key Event: Consummated an Initial Public Offering (IPO) on May 12, 2025, raising approximately $11.9 million in net proceeds.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1,781,255) | $(4,845,845) | $(1,078,357) |
| Operating Expenses | $1,844,239 | $4,872,511 | $999,482 |
| Cash and Equivalents (End of Period) | $6,986,617 | $6,986,617 | $26,571 |
| Total Assets | $9,250,036 | $9,250,036 | $13,057 |
| Total Liabilities | $1,089,384 | $1,089,384 | $1,371,178 |
| Shareholders' Equity | $8,160,652 | $8,160,652 | $(1,358,121) |
Debt Status: Long-term convertible notes payable to related parties were fully converted to common stock upon the IPO. Current liabilities include $500,000 in notes payable to related parties and $567,633 in accounts payable/accrued expenses.
Material Changes vs. Prior Period
- Liquidity Transformation: Cash balances surged from $3,455 at year-end 2024 to nearly $7.0 million at September 30, 2025, driven by the IPO. Shareholders' equity shifted from a deficit of $(1.36) million to a positive $8.16 million.
- Expense Surge: Operating expenses increased significantly due to the ramp-up of clinical trials and public company compliance costs.
- R&D Expenses: Increased from $0 in Q3 2024 to $619,693 in Q3 2025, primarily driven by $557,000 in clinical trial costs.
- G&A Expenses: Increased from $299,999 in Q3 2024 to $1,224,546 in Q3 2025, driven by professional services, payroll, and stock-based compensation.
- Stock-Based Compensation: Significant non-cash charges were recorded in 2025 ($1.7 million for stock grants and $235k for options) compared to none in the prior year, reflecting IPO-related grants to executives and employees.
- Debt Conversion: Approximately $660,000 in principal and accrued interest from related-party convertible notes was converted into 297,133 shares of common stock during the IPO.
Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management believes current cash reserves ($6.99 million) are sufficient to fund operations for at least the next 12 months.
- Subsequent Event (Oct 15, 2025): The company paid a $700,000 non-refundable fee to D. Boral Capital to waive the Right of First Refusal and Lock-Up Agreements from the IPO underwriting agreement.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing material weaknesses including a lack of documented procedures, segregation of duties, and review controls over journal entries.
- Risks: The company has no revenue, expects to continue incurring substantial losses, and is dependent on regulatory approval for Apitox. Future financing may be required to sustain operations beyond the current runway.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $6.99 million cash balance against the current quarterly burn rate of approximately $1.8 million in operating losses.
- Subsequent Cash Outflow: Confirm the impact of the $700,000 waiver fee paid in October 2025 on the current cash position.
- Internal Control Remediation: Review the company's plan to address the material weaknesses in internal controls over financial reporting.
- Related Party Transactions: Monitor the remaining $500,000 notes payable and other related-party balances to ensure terms are arm's length.
- Clinical Milestones: Track progress on FDA approval for Apitox, as the business model relies entirely on this regulatory outcome.